Barinthus Biotherapeutics (STU:2AB) Cash Flow from Investing: €0.41 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2AB Barinthus Biotherapeutics PLC STU:2AB
14 GF Score
Price €0.48
GF Value €0.96
! 1 Warning Sign
View Full Analysis

What is Barinthus Biotherapeutics Cash Flow from Investing?

Barinthus Biotherapeutics STU:2AB -0.41% 14 Cash Flow from Investing is €0.41 Mil as of Mar. 2026. GuruFocus rates STU:2AB with a GF Score™ of 14/100 and a GF Value™ of €0.96. The stock has 1 warning sign investors should review.

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2026, Barinthus Biotherapeutics spent €0.00 Mil on purchasing property, plant, equipment. It gained €0.05 Mil from selling property, plant, and equipment. It spent €0.00 Mil on purchasing business. It gained €0.00 Mil from selling business. It spent €0.00 Mil on purchasing investments. It gained €0.00 Mil from selling investments. It paid €0.00Mil for net Intangibles purchase and sale. And it paid €0.00 Mil for other investing activities. In all, Barinthus Biotherapeutics gained €0.05 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2026.


Barinthus Biotherapeutics  (STU:2AB) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Barinthus Biotherapeutics's purchase of property, plant, equipment for the three months ended in Mar. 2026 was €0.00 Mil. It means Barinthus Biotherapeutics spent €0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Barinthus Biotherapeutics's sale of property, plant, equipment for the three months ended in Mar. 2026 was €0.05 Mil. It means Barinthus Biotherapeutics gained €0.05 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Barinthus Biotherapeutics's purchase of business for the three months ended in Mar. 2026 was €0.00 Mil. It means Barinthus Biotherapeutics spent €0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Barinthus Biotherapeutics's sale of business for the three months ended in Mar. 2026 was €0.00 Mil. It means Barinthus Biotherapeutics gained €0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Barinthus Biotherapeutics's purchase of investment for the three months ended in Mar. 2026 was €0.00 Mil. It means Barinthus Biotherapeutics spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Barinthus Biotherapeutics's sale of investment for the three months ended in Mar. 2026 was €0.00 Mil. It means Barinthus Biotherapeutics gained €0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Barinthus Biotherapeutics's net Intangibles purchase and sale for the three months ended in Mar. 2026 was €0.00 Mil. It means Barinthus Biotherapeutics paid €0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Barinthus Biotherapeutics's cash from discontinued investing activities for the three months ended in Mar. 2026 was 0.00 Mil. It means Barinthus Biotherapeutics paid €0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Barinthus Biotherapeutics's cash from other investing activities for the three months ended in Mar. 2026 was €0.00 Mil. It means Barinthus Biotherapeutics paid €0.00 Mil for other investing activities.


Barinthus Biotherapeutics Cash Flow from Investing Related Terms


Barinthus Biotherapeutics Cash Flow from Investing Historical Data

* Premium members only.

The historical data trend for Barinthus Biotherapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Barinthus Biotherapeutics Cash Flow from Investing Chart

Barinthus Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow from Investing
Get a 7-Day Free Trial -11.43 -5.43 -4.96 -0.85 0.36

Barinthus Biotherapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 0.38 0.00 0.05 0.00
STU:2AB
14GF Score
Barinthus Biotherapeutics PLC STU:2AB
Cash Flow from Investing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Barinthus Biotherapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Barinthus Biotherapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2025 is calculated as:

Barinthus Biotherapeutics's Cash Flow from Investing for the quarter that ended in Mar. 2026 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Investing of €0.41 Mil mean?
Barinthus Biotherapeutics (STU:2AB) has a Cash Flow from Investing of €0.41 Mil as of Mar. 2026. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Barinthus Biotherapeutics and its competitors.
Is Barinthus Biotherapeutics' Cash Flow from Investing too high?
Barinthus Biotherapeutics' current Cash Flow from Investing is €0.41 Mil. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' Cash Flow from Investing compare to CRVO and ALGS?
Barinthus Biotherapeutics' Cash Flow from Investing of €0.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Investing for a Biotechnology company?
A good Cash Flow from Investing depends on the Biotechnology industry context. However, Cash Flow from Investing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Investing mean?
A high Cash Flow from Investing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for Barinthus Biotherapeutics and its competitors. Barinthus Biotherapeutics's current Cash Flow from Investing is €0.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current Cash Flow from Investing of €0.41 Mil. The stock's GF Value™ is €0.96, compared to a current price of €0.48 — trading 49.8% below its estimated fair value. The current Cash Flow from Investing is €0.41 Mil. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Investing calculated?
Cash Flow from Investing is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current Cash Flow from Investing is €0.41 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of €0.48 is trading 49.8% below its estimated GF Value™ of €0.96.

Key valuation signals for STU:2AB:

  • Cash Flow from Investing: €0.41 Mil
  • GF Value™: €0.96 vs. price of €0.48 (49.8% below fair value)
  • GF Score™: 14/100 with 1 warning sign

No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Barinthus Biotherapeutics Business Description

Other Exchanges BRNS:USA
Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score

Get the complete analysis for STU:2AB

Cash Flow from Investing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.48
Price
€0.96
GF Value